It is anticipated that a better understanding of the proximal transcriptional events triggered by cell-penetrating peptides that target ATF5, CEBPB and CEBPD will better define their mechanisms of action, which in turn will inform their best use in therapies for treatment of brain and other cancers. The gene discussed is CEBPB; the disease is cancer.